gbola amusa md cfa head hc research
sale trade et
viral news genet medicin roch partner submit bla hema
highlight week decemb decemb unrat announc collabor
roch unrat gene therapi gt duchenn muscular dystrophi dmd
term agreement roch acquir ex-u right launch commerci exchang sarepta
receiv bn up-front mm cash mm sarepta stock price per share
bn regulatori sale mileston royalti net sale anticip mid-teen sarepta roch
equal share global develop expens unrat announc submit bla
fda gt valoctocogen roxaparvovec adult hemophilia applic incorpor
phase interim data plu phase i/ii data separ compani announc
valid valoctocogen roxaparvovec review acceler assess begin
januari astella pharma unrat announc acquisit xypho bioscienc privat astella
pay mm up-front potenti futur mileston total transact valu mm xypho develop
cell-bas platform cancer therapi base engin receptor ligand pair modifi receptor
express natur immun cell engin chimer antigen receptor cell target-direct
molecul incorpor engin ligand direct cytotox activ
look forward decemb januari happi holiday
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
spark drop coverag close gmpt alpha decemb amusa
drop coverag roch unrat decemb
announc roch complet acquisit spark
close long-qure/short-onc genet medicin pair trade gmpt open novemb long-
qure/short-onc pair trade success associ alpha gener day
success close long-qure/short-onc gmpt brought chardan track record gmpt
success rate gmpt current one posit still open see decemb research
genet medicin news decemb decemb
unrat announc licens deal roch gt dmd decemb
unrat announc select addit nasdaq biotechnolog index decemb
buy announc departur chief medic offic dr howard kaufman decemb
unrat file bla gt valoctocogen roxaparvovec hemophilia decemb
unrat announc valid valoctocogen roxaparvovec hemophilia decemb
unrat announc appoint dr christina coughlin chief medic offic decemb
pleas refer import disclosur inform regul analyst certif found page report
unrat transfer unrat ind gt hemophilia decemb
ucsd publish deliveri via spinal subpial administr decemb
 publish report system enrich modifi cell decemb
univers lausann publish express tumor antigen-direct t-cell decemb
astella unrat announc acquisit xypho bioscienc privat mm decemb
astella pharma announc acquisit xypho bioscienc mm paid upon close addit
up-front payment potenti mileston could bring total valu transact mm
xypho develop immuno-oncolog platform design target immun cell tumor
compon engin receptor unabl bind natur ligand modifi inert receptor
design express immun cell compon set ligand design bind exclus
modifi receptor function molecul includ antibodi fuse ligand use target
transgen immun cell tumor
unrat announc activ ind gt neuronopath gaucher di decemb
gnpx unrat file preliminari prospectu offer share common stock decemb
compani mention report
page
select catalyst genet medicin coverag
figur regenxbio rocket solid uniqur expect import data read-out
initi phase i/ii clinic trial huntington diseas
initi phase i/ii trial dmd nationwid children hospit
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
submit ind methylmalon acidemia mma
present interim data cohort steroid prophyl pi/ii studi hofh
initi dose phase trial hemophilia
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
file ind huntington diseas program
present preclin data new gt program fabri pomp defici
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
page
select catalyst outsid genet medicin coverag
initi phase ib trial beta-thalassemia
initi clinic trial charcot-marie-tooth type
micro-dystrophin initi pivot trial duchenn muscular dystrophi
initi phase ii studi overact bladder
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
file ind inherit amyotroph later sclerosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
lentiglobin initi phase studi sickl cell diseas
zynteglo initi roll bla submiss fda tdt
file ind gangliosidosi
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma buy lysogen oncosec medic oxford biomedica neutral vbl buy
figur select price movement week end dec vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm appli genet therapytickerratingccm ptupsideclosechang changemc mm arrowhead gene editingtickerratingccm ptupsideclosechang changemc mm pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid technolog pharmaceut
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis feldan recombinet trucod gene repair verv technolog pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
ultragenyx genetx
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
